NCT06463717View on ClinicalTrials.gov

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

RecruitingOBSERVATIONAL
Enrollment

210

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 30, 2028

Study Completion Date

December 31, 2028

Conditions
Multiple MyelomaMinimal Residual Disease
Interventions
DRUG

Transplant, Autologous

High-dose melphalan followed by autologous stem cell transplantation

DRUG

Chemotherapy drug

Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone

Trial Locations (1)

310000

RECRUITING

The First Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

The Affiliated Hospital of Medical College, Ningbo University

OTHER

collaborator

Dongyang People's Hospital

OTHER

lead

First Affiliated Hospital of Zhejiang University

OTHER